Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax， and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS - a Multicenter, Single Arm, Prospective Clinical Study

Lina Xing, Zijing Guo, Chen Huang, Hongmei Jing, Shukai Qiao

Blood (2024) 144 (Supplement 1): 6057.

https://doi.org/10.1182/blood-2024-201929

Published: 2024

Journal Articles

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2024-205492

Published: 2024

Journal Articles

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Yuan Yang, Ping Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2024-204870

Published: 2024

Journal Articles

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2024-207720

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Ping Yang, Chunyuan Li, Shuozi Liu, Yuan Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6305.

https://doi.org/10.1182/blood-2024-205002

Published: 2024

Journal Articles

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6303.

https://doi.org/10.1182/blood-2024-204939

Published: 2024

Journal Articles

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Shuozi Liu, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Ping Yang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2024-204877

Published: 2024

Journal Articles

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Lingli Wang, Jinjie Gao, Wei Wan, Fei Dong, Jing Wang, Weilong Zhang, Ping Yang, Lan Ma, Wei Zhao, Jijun Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2024-205570

Published: 2024

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Chunyuan Li, Jinjie Gao, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6339.

https://doi.org/10.1182/blood-2024-205068

Published: 2024

Journal Articles

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Ping Yang, Chunyuan Li, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6338.

https://doi.org/10.1182/blood-2024-205042

Published: 2024

Journal Articles

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Xiaoyu Hao, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2024-204938

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Yuankai Shi, Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian

Blood (2024) 144 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2024-200499

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Weidong Ding, Xiaoxuan Xue, Haoyu Qin, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2024-203031

Published: 2024

Journal Articles

Targeting p53 Improves Drug Resistance in Mantle Cell Lymphoma By Regulating Mitophagy-Dependent Ferroptosis

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2024-205447

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

Jiefei Bai, Hui Liu, Jiangtao Li, Ting Wang, Chunli Zhang, Yazi Yang, Xiaoya Yun, Jingjing Yin, Long Qian, Fei Zhao, Ru Feng, Hongmei Jing

Blood (2024) 144 (Supplement 1): 7896.

https://doi.org/10.1182/blood-2024-193714

Published: 2024

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax， and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS - a Multicenter, Single Arm, Prospective Clinical Study

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Targeting p53 Improves Drug Resistance in Mantle Cell Lymphoma By Regulating Mitophagy-Dependent Ferroptosis

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only